Navigation Links
A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
Date:3/8/2013

ation therapy is difficult to manage well, even if closely monitored, particularly if they take medicines or foods that affect these enzymes.  Recent data shows that these drug metabolizing enzymes are down regulated in patients with chronic renal dysfunction or failure which may explain the sub-optimal anti-coagulation control with warfarin or with the novel non-monitored OACs in these patients.

Monitoring the effectiveness of warfarin in many cases requires patients to travel frequently to a local clinic to have their anticoagulation status checked and, if needed, doses adjusted.  Recently, perhaps due to reimbursement by healthcare providers, there has been an increase in patient self-monitoring and management of anticoagulation therapy that is currently only applicable to VKOR inhibitors such as tecarfarin. Ultimately, this system could provide many patients with a cost-effective management of anticoagulation therapy with a better patient compliance than with new oral non-monitored OACs.

About Tecarfarin

Tecarfarin (ATI-5923) is potentially a best-in-class orally active vitamin K epoxide (VKOR) inhibitor that was specifically designed to avoid CYP2C9 dependent metabolism and to avoid transport by P-gp. This may mean tecarfarin will need less monitoring than warfarin, potentially resulting in better patient compliance if used together with widely available self-monitoring systems. Unlike the novel non-monitored OACs, tecarfarin has an antidote, vitamin K that is readily available and can be used to rapidly reverse the anticoagulation effect of tecarfarin in an emergency. If approved, tecarfarin could become a superior anticoagulation management solution to warfarin.

About Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has 3 programs in mid - to late - clinical stage developm
'/>"/>

SOURCE Armetheon, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Marta Rendon, MD, founder of the ... Raton , FL and international key opinion leader in dermatology, ... the United States to attend the international ... Turkey . Here, at this gathering of over 600 ... renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)...  Surgical Theater, LLC, announced today that their technology ... opening of Europe,s first simulation ... The SuRgical Planner (SRP) and the Surgical Navigation Advanced ... their 3D navigation and augmented reality capabilities in the ... and Chair, Department of Neurosurgery at Mount Sinai Health ...
(Date:11/24/2014)... 24, 2014  Pifflers United Chronic and Invisible ... release of results of a study of ActiPatch®, ... self-management of fibromyalgia pain. The results demonstrated that ... very significant clinically meaningful pain reduction can be ... with fibromyalgia used ActiPatch® for 7 days and ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... Tengion, Inc. (NASDAQ: TNGN ), a ... Vice President Finance and Chief Financial Officer of Tengion, ... Health Care Conference on Wednesday, November 30, 2011, at ... webcast of the presentation can be accessed at ...
... Nov. 21, 2011 /PRNewswire-Asia/ -- Sundia MediTech Company Inc., a ... the company was named one of the 50 best companies ... was announced at an October ceremony in Shanghai. This is ... after it was previously named in 2007 and 2008. ...
Cached Medicine Technology:Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... 2014 A new sports massage ... pain-relief service and massage therapy provider, announced it ... This newest sports massage is a ... between traditional sports massage and ESM is that ... very own "reset button,” and ESM can increase ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 SWAccessControl.com ... locks. As a matter of fact, the company is a ... its brand new magnetic locks are available at discounted prices, ... our new range of magnetic locks. This time, all of ... are popular at home and abroad, so I have confidence ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... put the outbreak in doubt. The mystery began Sept. ... cough, typically heralded by a runny// nose, sneezing, slight fever, ... ,Then in last September through early November, about three ... other symptoms suggesting that they, too, were stricken with the ...
... groups, with relatively little genetic differentiation among the people from ... study. ,Although the study used participants that may ... suggest that the frequencies of many genetic variants are distinctive ... Indian American scientist who led the study said. ...
... that neural stem cells will eventually be useful for ... and multiple sclerosis. But there may also be another ... cells. ,A Perspective article in PLoS Medic ine, ... discusses a new study in mice, published in the ...
... Drug Administration (FDA) will release its approval for consumption of ... ,Two federal scientists, Larisa Rudenko and John C. Matheson. ... milk of cloned animals and their offspring. “On no basis ... from normal animals,” they say. ,A formal recommendation ...
... was 14 months old that left her gasping for breath.// ... to trigger an allergic reaction in people allergic to it. ... a landmark experiment that set to discover-'Could eating tiny amounts ... bodies to overcome severe food allergies?' ,Preliminary results ...
... children may have a shorter life span than those with few ... new study.// ,Researchers led by Dustin Penn and Ken Smith ... living in Utah between 1860 and 1985, who bore a total ... an average of eight children each, but family size ranged from ...
Cached Medicine News:Health News:Indians Make One Major Human Race: US Study 2Health News:Is Your Child Allergic To Peanuts? 2
... that need an advanced ... Vision,Premier Holter System provides ... Vision Premier system,adds expanded ... comprehensive list of diagnostic,codes ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... three contrast levels (high, 9.5 % and 6%) ... test is designed to detect very subtle changes ... evaluation or due to refractive surgery. The upper ... contrast and acuity levels as the lower two ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: